达安基因
(002030)
| 流通市值：81.68亿 | | | 总市值：81.68亿 |
| 流通股本：14.03亿 | | | 总股本：14.03亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 169,136,638.98 | 853,024,340.06 | 591,050,057.91 | 400,381,368.24 |
| 营业收入 | 169,136,638.98 | 853,024,340.06 | 591,050,057.91 | 400,381,368.24 |
| 利息收入 | 0 | 0 | 0 | 0 |
| 已赚保费 | 0 | 0 | 0 | 0 |
| 手续费及佣金收入 | 0 | 0 | 0 | 0 |
| 二、营业总成本 | 238,175,840.05 | 1,058,064,537.31 | 695,779,975.01 | 454,312,338.72 |
| 营业成本 | 116,639,813.97 | 532,743,357.51 | 354,750,208.8 | 235,349,667.91 |
| 利息支出 | 0 | 0 | 0 | 0 |
| 手续费及佣金支出 | 0 | 0 | 0 | 0 |
| 退保金 | 0 | 0 | 0 | 0 |
| 赔付支出净额 | 0 | 0 | 0 | 0 |
| 提取保险合同准备金净额 | 0 | 0 | 0 | 0 |
| 保单红利支出 | 0 | 0 | 0 | 0 |
| 分保费用 | 0 | 0 | 0 | 0 |
| 税金及附加 | 957,379.27 | 9,533,974.98 | 4,212,451.3 | 2,786,935.4 |
| 销售费用 | 45,354,577.5 | 208,135,259.78 | 105,810,189.55 | 62,995,789.03 |
| 管理费用 | 31,562,428.43 | 147,052,511.51 | 111,681,235.85 | 68,056,335.76 |
| 研发费用 | 53,947,875.38 | 225,668,337.11 | 167,134,295.16 | 118,905,329.41 |
| 财务费用 | -10,286,234.5 | -65,068,903.58 | -47,808,405.65 | -33,781,718.79 |
| 其中:利息费用 | 1,220,515.45 | 9,744,538.33 | 5,742,298.28 | 4,457,798.91 |
| 其中:利息收入 | 13,156,077.19 | 69,372,365.34 | 53,386,221.47 | 36,752,757.39 |
| 加:公允价值变动收益 | 200,727,294.7 | -175,745,759.4 | -119,224,149.48 | -306,861,205.58 |
| 加:投资收益 | -24,752,707.19 | -253,838,060.16 | -130,108,689.2 | -29,960,605.45 |
| 净敞口套期收益 | 0 | 0 | 0 | 0 |
| 汇兑收益 | 0 | 0 | 0 | 0 |
| 资产处置收益 | 4,911.43 | 9,096,715.23 | 2,077,739.9 | -1,160,087.84 |
| 资产减值损失(新) | -3,490,664.44 | -75,039,742.89 | -113,954.43 | -85,860.45 |
| 信用减值损失(新) | -22,202,238.09 | -407,831,786.93 | -247,295,765.62 | -107,629,286.33 |
| 其他收益 | 11,929,429.77 | 40,793,337.41 | 32,632,643.94 | 24,890,695.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 93,176,825.11 | -1,067,605,493.99 | -566,762,091.99 | -474,737,320.48 |
| 加:营业外收入 | 793,129.91 | 2,584,173.89 | 436,836.52 | 128,416.31 |
| 减:营业外支出 | 140,725.39 | 6,142,074.3 | 1,552,357.49 | 1,406,707.59 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 93,829,229.63 | -1,071,163,394.4 | -567,877,612.96 | -476,015,611.76 |
| 减:所得税费用 | 42,566,394.4 | -132,050,533.38 | -66,376,049.48 | -78,369,791.08 |
| 六、净利润 | 51,262,835.23 | -939,112,861.02 | -501,501,563.48 | -397,645,820.68 |
| 持续经营净利润 | 51,262,835.23 | -939,112,861.02 | -501,501,563.48 | -397,645,820.68 |
| 终止经营净利润 | 0 | 0 | 0 | 0 |
| 归属于母公司股东的净利润 | 52,924,282 | -925,169,864.75 | -502,719,727.25 | -399,219,058.46 |
| 少数股东损益 | -1,661,446.77 | -13,942,996.27 | 1,218,163.77 | 1,573,237.78 |
| (一)基本每股收益 | 0.04 | -0.66 | -0.36 | -0.28 |
| (二)稀释每股收益 | 0.04 | -0.66 | -0.36 | -0.28 |
| 八、其他综合收益 | -38,440.51 | -3,309,277.01 | 125,820.15 | 485,109.64 |
| 归属于母公司股东的其他综合收益 | -22,401.25 | -3,491,876.88 | 162,725.34 | 445,072.4 |
| 九、综合收益总额 | 51,224,394.72 | -942,422,138.03 | -501,375,743.33 | -397,160,711.04 |
| 归属于母公司股东的综合收益总额 | 52,901,880.75 | -928,661,741.63 | -502,557,001.91 | -398,773,986.06 |
| 归属于少数股东的综合收益总额 | -1,677,486.03 | -13,760,396.4 | 1,181,258.58 | 1,613,275.02 |
| 公告日期 | 2025-04-30 | 2025-03-29 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |